The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published in the Journal of the National Cancer Institute. The researchers found that Nelfinavir inhibited the growth of HER2-positive tumors in mice. They also found that the concentrations of Nelfinavir needed to inhibit HER2-positive cancer cells in vitro are consistent with dosage regimens used for HIV patients. Read more here.
Study mentioned: Shim JS, et al. Selective Inhibition of HER2-Positive Breast Cancer Cells by the HIV Protease Inhibitor Nelfinavir. J Natl Cancer Inst. 2012 Oct 5. [Epub ahead of print] PMID: 23042933
No comments:
Post a Comment